How about a 50% gain in one week? That's the worst performance among these health-care high flyers.
The details behind Roche's deal with Pacific Biosciences of California.
Is Pacific Biosciences' new arrangement with Roche a good deal? Mr. Market gives PacBio's deal a big thumbs up.
Two important things you need to know about the future of Illumina.
The medical-technology company isn't well known, but investors have pushed Waters stock up toward all-time records.
With the potential for an epidemic at hand, we look at things from a glass-half-full perspective.
Let's see what the numbers say about Illumina (ILMN).
Thermo Fisher buys Life Technologies for $13.6 billion, but is it a good deal?
Who's going to win the bidding war over Life Technologies, and will it pay off big for investors?
Will PacBio's Q4 results slow the stock's big 2013 surge?